Story · Medicine & Biotech
Gilberto Lopes on Ivonescimab and the FDA Decision: When Is Progression-Free Survival Enough?
1 outlet · first reported by OncoDaily on
Gilberto Lopes, Chief of the Division of Medical Oncology at the Sylvester Comprehensive Cancer Center, shared on LinkedIn: “Ivonescimab, the FDA, and a difficult question in oncology: When is progression-free (OncoDaily)
Coverage, in order
-
Gilberto Lopes on Ivonescimab and the FDA Decision: When Is Progression-Free Survival Enough?Gilberto Lopes, Chief of the Division of Medical Oncology at the Sylvester Comprehensive Cancer Center, shared on LinkedIn: “Ivonescimab, the FDA, and a difficult question in oncology: When is progression-free
Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.